FEED

#4995
ENvue Medical, Inc. - Common Stock
0.3 4 USD
-0.08%
Market Price
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
0.34
0.34
Yıllık Aralık
0.29
6.09
Günlük Değişim
-8.11%
Aylık Değişim
+9.68%
6 Aylık Değişim
-82.65%
Yıllık Değişim
-92.64%
Önceki Kapanış
0.3 7
Open
0.3 4
Düşük
0.3 4
Yüksek
0.3 4
Hacim
2
Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler Documents

2026

Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Envue Medical, Inc. quarterly report, Q2 FY2026
10-Q
Quarterly report, Q1 FY2026
Envue Medical, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Envue Medical, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Envue Medical, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Envue Medical, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Envue Medical, Inc. current report, Q4 FY2025
8-K

Envue Medical, Inc. current report, Q3 FY2025

Full document

Business Context and Reporting Period

This Form 8-K is filed by NanoVibronix, Inc. (trading symbol: NAOV) on July 11, 2025. The filing reports on a Special Meeting of Stockholders held on this date. Note: The request metadata references "Envue Medical, Inc.," but the filing text explicitly identifies the registrant as NanoVibronix, Inc.

Key Financial Metrics

This filing is an "Other Events" report (Item 8.01) regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

  • Meeting Adjournment: The Special Meeting of Stockholders was opened and immediately adjourned due to an absence of a quorum. No business was conducted.
  • Reconvened Meeting: The meeting will be reconvened virtually on July 17, 2025, at 10:00 a.m. Eastern Time.
  • Proxy Deadline: The new deadline for submitting proxies for the reconvened meeting is July 16, 2025, at 11:59 p.m. Eastern Time.
  • Record Date: The record date for voting eligibility remains May 16, 2025.

Guidance, Outlook, and Risks

The filing includes standard forward-looking statements regarding the risks associated with the company's operations and the pending business combination. Key risks highlighted include:

  • The inability to consummate a business combination within the required timeframe.
  • The level of shareholder redemptions and the subsequent impact on funds available in the trust account to complete an initial business combination.
  • General risks detailed in the Annual Report on Form 10-K for the year ended December 31, 2024.

Management commentary is limited to the procedural details of the meeting adjournment and the instructions for the reconvened meeting.

Investor Verification Checklist

  • Verify the reconvened meeting date and time: July 17, 2025, at 10:00 a.m. ET.
  • Confirm the new proxy submission deadline: July 16, 2025, at 11:59 p.m. ET.
  • Review the Definitive Proxy Statement filed on June 20, 2025, for details on the proposals to be voted on.
  • Check the Annual Report (Form 10-K) filed on March 31, 2025, for updated risk factors and executive officer interests.
  • Confirm whether existing proxy votes remain valid for the reconvened meeting (the filing states they do).